Last updated: September 8, 2026
Fluciclovine F-18, marketed as Axumin, is an FDA-approved PET imaging agent for detecting suspected recurrent prostate cancer. Its commercial position has weakened since 2021 as prostate-specific membrane antigen, or PSMA, PET agents gained regulatory approval and physician adoption. Axumin remains commercially available, but its market is mature, its five-year new chemical entity exclusivity has expired, and public financial reporting does not disclose product-level revenue.
What is the FDA status of fluciclovine F-18?
The FDA approved Axumin on May 27, 2016, under NDA 208054 for PET imaging in men with suspected recurrent prostate cancer based on elevated prostate-specific antigen levels after prior treatment.[1]
| Attribute |
Fluciclovine F-18 |
| Brand name |
Axumin |
| Active ingredient |
Fluciclovine F-18 injection |
| Sponsor at approval |
Blue Earth Diagnostics |
| Current commercial owner |
Bracco Imaging |
| FDA application |
NDA 208054 |
| Approval date |
May 27, 2016 |
| Imaging modality |
PET |
| Primary use |
Detection and localization of recurrent prostate cancer |
| Physical half-life |
Approximately 110 minutes |
| Regulatory category |
Diagnostic radiopharmaceutical |
| NCE exclusivity |
Five years, expired in May 2021 |
Axumin is administered intravenously and used with PET imaging. Its short radioactive half-life requires regional or local radiopharmacy production and distribution. That supply model creates operating constraints that do not apply to conventional oral medicines.
The FDA has not classified fluciclovine F-18 as a biologic. Biosimilar competition is therefore not applicable. Potential competition would come from another fluciclovine product, an alternative PET tracer, or a competing imaging modality.
When did fluciclovine F-18 lose regulatory exclusivity?
Axumin's five-year new chemical entity exclusivity expired in May 2021. The expiration removed the FDA's principal period of statutory protection against submission of certain competing applications.
Regulatory exclusivity and patent protection are separate. Expiration of NCE exclusivity did not automatically authorize a competing manufacturer to commercialize fluciclovine F-18. A competitor would still need to address applicable patents, FDA manufacturing requirements, radiopharmaceutical quality controls, and commercial distribution requirements.
The practical effect of the 2021 exclusivity expiration has been limited by the product's specialized manufacturing and distribution model. Fluciclovine F-18 is not a conventional tablet or injectable drug that can be manufactured centrally and shipped nationally. A competing product would need access to cyclotron capacity, validated synthesis processes, radiochemical quality testing, and a clinical distribution network.
What patents protect Axumin and fluciclovine F-18?
Axumin's commercial protection has historically relied on patents covering fluciclovine imaging technology, radiolabeled amino-acid compounds, and related diagnostic uses. The precise Orange Book listing and expiration status should be assessed against the current FDA publication because patent listings, terminal disclaimers, pediatric extensions, and regulatory extensions can affect the effective date.
Publicly reported Axumin patent coverage has extended beyond the 2021 FDA exclusivity expiration, with patent protection generally described as reaching into the late 2020s or early 2030s depending on the claim and jurisdiction.[2]
What types of Axumin claims matter commercially?
The relevant protection can include:
- Claims to fluorine-18-labeled amino-acid compounds.
- Claims covering fluciclovine formulations or injectable compositions.
- Claims covering PET imaging of recurrent prostate cancer.
- Claims relating to preparation, synthesis, purification, or quality control.
- Foreign counterparts in Europe, Japan, Canada, and other regulated markets.
Patent risk is claim-specific. A patent covering a particular method of use may not prevent a rival from developing a different indication or imaging protocol. A composition or manufacturing patent can create a broader barrier if the competing product requires the same active ingredient or production route.
Is Axumin listed in the Orange Book?
Axumin is an approved prescription drug and has been associated with FDA patent-listing and exclusivity information. Orange Book analysis should distinguish between:
- Listed patents that may support an FDA patent certification.
- Patents that have expired or are no longer enforceable.
- Method-of-use patents that apply only to labeled indications.
- Patents that remain commercially relevant but are not listed in a way that controls an ANDA pathway.
Because fluciclovine F-18 is a radiopharmaceutical with a specialized manufacturing pathway, Orange Book status alone does not determine the full competitive barrier.
Have companies filed Paragraph IV challenges against Axumin?
There is no widely reported, market-defining Paragraph IV litigation campaign against Axumin comparable to the challenges seen for high-revenue small-molecule therapies.
That result reflects the product's economics. A Paragraph IV case generally requires a credible generic or alternative sponsor with sufficient commercial incentive. Axumin's declining market share, short radioactive half-life, regional distribution requirements, and competition from PSMA PET reduce the expected return from a conventional generic challenge.
A competitor could pursue an abbreviated pathway or another FDA route, but the commercial opportunity would depend on demonstrating that its product is substitutable in clinical practice and reimbursed by payers. The technical burden includes radiochemical identity, radionuclide purity, sterility, stability, synthesis reproducibility, and delivery timing.
How has the competitive landscape changed for Axumin?
Axumin's primary competitive threat is PSMA-targeted PET imaging rather than a direct fluciclovine generic.
| Product |
Active agent |
FDA approval |
Strategic position |
| Axumin |
Fluciclovine F-18 |
2016 |
Earlier-generation imaging option for recurrent prostate cancer |
| Illuccix |
Ga-68 gozetotide |
2021 |
PSMA-targeted PET imaging |
| Pylarify |
Piflufolastat F-18 |
2021 |
F-18 PSMA PET agent with broad commercial distribution |
| Locametz |
Ga-68 gozetotide |
2022 |
PSMA PET imaging for prostate cancer |
PSMA agents benefit from disease-target specificity and strong clinical adoption in biochemical recurrence and advanced prostate cancer. Piflufolastat F-18 also has an operational advantage over gallium-68 products in some settings because fluorine-18 production can support broader distribution from regional manufacturing sites.
Axumin can still be used when PSMA imaging is unavailable, when a physician prefers its clinical profile, or when local radiopharmacy access and payer coverage favor the product. Its competitive position is weaker in centers that have invested in PSMA PET infrastructure.
How does Axumin compare with Pylarify?
| Factor |
Axumin |
Pylarify |
| Target |
Amino-acid transport activity |
PSMA |
| FDA approval |
2016 |
2021 |
| Isotope |
F-18 |
F-18 |
| Disease focus |
Recurrent prostate cancer |
Prostate cancer imaging across specified clinical settings |
| Commercial maturity |
Mature and declining |
Newer, expanding |
| Competitive risk |
Faces substitution by PSMA PET |
Benefits from newer clinical positioning |
| Distribution |
Requires radiopharmacy logistics |
Also requires radiopharmacy logistics |
The comparison is unfavorable for Axumin because Pylarify competes for the same prostate cancer PET budgets while presenting a newer target and a more current clinical narrative.
What is the financial trajectory of fluciclovine F-18?
Axumin's financial trajectory is best characterized as launch, adoption, strategic acquisition, and erosion from PSMA substitution.
| Period |
Financial and commercial development |
| 2016 |
FDA approval creates the first major commercial opportunity for fluciclovine PET imaging in recurrent prostate cancer |
| 2017-2020 |
Blue Earth expands radiopharmacy, physician, and payer access |
| 2021 |
NCE exclusivity expires; Bracco Imaging acquires Blue Earth Diagnostics |
| 2021-2022 |
PSMA PET products receive FDA approvals |
| 2022 onward |
Axumin faces increasing substitution and reduced growth potential |
| Current trajectory |
Mature product with declining strategic priority relative to PSMA agents |
Bracco Imaging acquired Blue Earth Diagnostics in 2021 in a transaction reported at approximately $450 million upfront, with additional consideration tied to transaction terms and performance.[3] The acquisition gave Bracco an established oncology imaging platform and commercial access to Axumin.
Bracco does not publicly report Axumin revenue as a standalone product in the same manner as a public pharmaceutical company reporting product sales. Available public disclosures therefore do not support a reliable product-level revenue estimate or precise annual decline rate.
The commercial value of Axumin now depends on cash generation from an installed radiopharmacy and customer base, not on large future growth. Important variables include:
- PET scan volume for biochemical recurrence.
- The pace of PSMA PET conversion.
- Reimbursement rates under Medicare and commercial insurance.
- Radiopharmacy utilization and geographic density.
- Manufacturing yield and isotope availability.
- Physician familiarity and local ordering habits.
- The number of sites with access to PSMA alternatives.
What reimbursement factors affect Axumin demand?
Medicare and commercial payer reimbursement strongly influence PET tracer use. Axumin reimbursement is connected to the PET procedure, the radiopharmaceutical supply, hospital outpatient payment systems, and local payer policy.
The principal commercial risk is clinical substitution rather than a simple reimbursement cut. If a site receives comparable or better reimbursement for PSMA PET, physicians and hospital administrators have an incentive to shift tracer utilization.
Axumin's short half-life creates a second economic constraint. Missed appointments, delayed scans, unused doses, and low daily procedure volume can reduce radiopharmacy margins. High-volume centers can manage these risks more efficiently than smaller sites.
What manufacturing and intellectual-property barriers protect the market?
Fluciclovine F-18 production requires more than access to a patent license. A commercial entrant would need:
- A qualified cyclotron or contracted isotope supply.
- An automated synthesis process.
- Sterile production under applicable current good manufacturing practice requirements.
- Validated analytical testing for identity, potency, radionuclidic purity, and radiochemical purity.
- A distribution system capable of delivering doses before radioactive decay materially reduces activity.
- FDA approval and site-specific regulatory compliance.
- Hospital and imaging-center contracting.
The isotope's half-life is a physical barrier to nationwide inventory management. Manufacturing must be synchronized with scheduled patient demand. These requirements limit the number of viable suppliers even after statutory exclusivity and some patents expire.
What patent litigation and settlement agreements affect Axumin?
No major public patent settlement has established a defined generic launch date for fluciclovine F-18. No widely reported litigation has produced an agreed entry date comparable to settlements involving high-volume prescription medicines.
The absence of a major settlement does not eliminate patent risk. A future entrant would need to evaluate:
- Orange Book-listed patents.
- Unlisted composition, process, and formulation patents.
- Patent term adjustments and terminal disclaimers.
- Foreign patent families.
- FDA approval-pathway requirements.
- Potential tort and patent litigation after launch.
The most credible near-term competitive scenario is continued substitution by PSMA agents rather than a conventional generic launch triggered by Paragraph IV litigation.
What is the geographic market position of fluciclovine F-18?
Axumin's geographic reach is constrained by radiopharmacy infrastructure. Markets with dense PET networks, nearby cyclotrons, and high prostate cancer imaging demand are more economically attractive.
The United States remains the principal commercial market because of its early FDA approval, established reimbursement pathways, and Blue Earth's historical distribution network. International markets depend on separate regulatory approvals, local manufacturing capacity, and national reimbursement.
Geographic protection is therefore mixed. Patent rights may be country-specific, but practical supply protection depends on local production and distribution. A competitor can have patent freedom in a country and still lack a viable commercial supply chain.
How strong is the Axumin patent estate?
Axumin's patent estate is commercially meaningful but strategically weaker than it was before PSMA PET competition emerged.
| Strength factor |
Assessment |
| FDA exclusivity |
Expired |
| Direct generic incentive |
Limited |
| Product differentiation |
Weakened by PSMA imaging |
| Manufacturing complexity |
Moderate to high barrier |
| Short half-life |
Meaningful logistical barrier |
| Patent value |
Depends on surviving composition, method, and process claims |
| Litigation exposure |
No major public challenge defining market entry |
| Long-term growth |
Limited |
The estate can delay direct fluciclovine competition, but it cannot prevent physicians from choosing a different approved PET tracer. Patent strength protects the product's route to market; it does not protect the prostate cancer PET market as a whole.
What generic launch scenarios exist for fluciclovine F-18?
Three scenarios are commercially plausible:
Direct fluciclovine competitor
A rival develops an equivalent fluciclovine F-18 product and enters after resolving applicable patents and FDA requirements. This would create direct price pressure but requires substantial radiopharmacy infrastructure.
Limited regional competition
A hospital system or regional radiopharmacy produces or distributes a competing product in selected markets. This scenario could pressure Axumin pricing locally without creating a national launch.
Therapeutic substitution by PSMA PET
PSMA agents continue to displace Axumin without a direct fluciclovine competitor. This is the most significant current risk because it does not require a patent challenge to Axumin.
Key Takeaways
- Axumin was FDA-approved in 2016 for PET imaging of suspected recurrent prostate cancer.
- Its five-year NCE exclusivity expired in May 2021.
- Bracco Imaging acquired Blue Earth Diagnostics in 2021 in a transaction reported at approximately $450 million upfront.
- Bracco does not publicly disclose standalone Axumin revenue, preventing a verified product-level financial forecast.
- PSMA agents, particularly Pylarify and Illuccix, are the main commercial threat.
- No major public Paragraph IV campaign or settlement currently defines Axumin's generic entry outlook.
- Manufacturing complexity, short radionuclide half-life, and radiopharmacy logistics remain meaningful barriers.
- The most likely erosion path is clinical substitution by PSMA PET rather than rapid direct generic entry.
- Axumin's patent value depends on the status of specific composition, formulation, method-of-use, and process claims in each jurisdiction.
- The product is commercially mature, with declining growth prospects but residual value in sites lacking PSMA access or retaining established Axumin workflows.
FAQs About Fluciclovine F-18 Market and Patent Risk
Is fluciclovine F-18 still approved by the FDA?
Yes. Axumin remains an FDA-approved fluciclovine F-18 PET agent for imaging suspected recurrent prostate cancer.
Does fluciclovine F-18 have biosimilar competition?
No. Fluciclovine F-18 is a small-molecule radiopharmaceutical, not a biologic. Biosimilar regulation does not apply.
Is Pylarify a generic version of Axumin?
No. Pylarify contains piflufolastat F-18 and targets PSMA. It is a competing PET radiopharmaceutical, not a fluciclovine F-18 generic.
Does Axumin have a publicly reported annual revenue figure?
No standalone, verified annual revenue figure is regularly disclosed by Bracco Imaging for Axumin.
What is the biggest commercial risk to Axumin?
The main risk is continued physician and payer migration to PSMA-targeted PET imaging, particularly Pylarify and gallium-68 PSMA products.
References
-
U.S. Food and Drug Administration. (2016). Axumin (fluciclovine F 18) injection: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
-
Bracco Imaging S.p.A. (2021). Bracco Imaging acquires Blue Earth Diagnostics. Bracco Imaging.
-
U.S. Food and Drug Administration. (2021). Pylarify (piflufolastat F 18) injection: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2021). Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection): Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2022). Locametz (gozetotide kit): Prescribing information. FDA.
